- Medison Urges Knight Therapeutics and Jonathan Goodman to Aggressively Pursue Opportunities Created by Distressed Opioid Case Targets
- Israeli Courts Rule Against Knight Therapeutics’ and Jonathan Goodman in Frivolous and Costly Litigation Aimed at Silencing Medison
- Medison Expresses Concerns over Knight Therapeutics’ Second Quarter Results and Demands Answers to Critical Questions from Jonathan Goodman
- MEDISON BIOTECH CONSIDERS REQUISITION OF SPECIAL MEETING OF SHAREHOLDERS OF KNIGHT THERAPEUTICS INC.
- Medison Biotech: Jonathan Goodman takes advantage of his own failure to create value, enriching himself at the expense of the shareholders of Knight Therapeutics